Ocrevus

Program Update!

Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).

Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.

For more information, please call the Help Desk at 844-672-6729.

Program offering

The OCREVUS Co-pay Program may help eligible commercially insured patients who have been prescribed OCREVUS with their drug costs, infusion costs or both.

Help with drug costs

$ 5

Patient pays as little as $5 for OCREVUS drug costs*

Benefit limit is $20,000 per year

Help with infusion costs

$ 5

Patient pays as little as $5 for infusion costs*

Benefit limit is $1500 for the first year and $1000 for each subsequent year

*Depending on how the health insurance plan applies manufacturer co-pay assistance for out-of-pocket costs or if they match the maximum benefit of the program, patients may owe more than $5.

Eligibility for help with drug costs

PATIENTS ARE ELIGIBLE IF THEY:

Have been prescribed OCREVUS for an FDA-approved indication
Are 18 years of age or older
Have commercial (private or nongovernmental) insurance. This includes plans available through state and federal health insurance exchanges
Do not receive support for OCREVUS from the Genentech Patient Foundation or any independent co-pay assistance foundations
Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)

Eligibility for help with infusion costs

PATIENTS ARE ELIGIBLE IF THEY:

Have been prescribed OCREVUS for an FDA-approved indication
Are 18 years of age or older
Have commercial (private or nongovernmental) insurance. This includes plans available through state and federal health insurance exchanges
Do not receive support for OCREVUS from independent co-pay assistance foundations^†
Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)
Do not live or get treatments in a restricted state (Massachusetts or Rhode Island)

^†Your patients may be able to use the OCREVUS Co-pay Program for their infusion costs if they are receiving OCREVUS from the Genentech Patient Foundation.

If a patient is not eligible for the OCREVUS Co-pay Program, there may be other options for co-pay assistance. Call (844) OCREVUS (844-627-3887) to speak to a Patient Navigator or visit OCREVUS.com to learn more.

Indication and Important Safety Information

Indications

OCREVUS is indicated for the treatment of:

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Primary progressive MS, in adults.

Contraindications

OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.

Warnings and Precautions

Infusion reactions:
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.

Infections:
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion

Reduction in Immunoglobulins:
Monitor the level of immunoglobulins at the beginning of treatment. Monitor during and after discontinuation of treatment with OCREVUS, until B-cell repletion, and especially when recurrent serious infections are suspected. Consider discontinuing OCREVUS in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins

Malignancies:
An increased risk of malignancy, including breast cancer, may exist with OCREVUS

Most Common Adverse Reactions
RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions.
PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.

For additional safety information, please see the [accompanying] full Prescribing Information and Medication Guide.

Program Update!

Program Offering and Eligibility

Program offering

Eligibility for help with drug costs

Eligibility for help with infusion costs

Indications

Contraindications

Warnings and Precautions